Zacks Rating on Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ) : The consensus on Johnson & Johnson (JNJ) based on 18 analyst recommendation on the company stock is 2.22, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 7 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 2 analyst believes that the stock is a Buy, which can produce decent returns in the future. 8 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating. 1 analyst sees the stock overvalued at current levels and advises a Strong Sell on the stock.

Johnson & Johnson (JNJ) : Currently there are 13 street experts covering Johnson & Johnson (JNJ) stock. The most bullish and bearish price target for the stock is $142 and $93 respectively for the short term. The average price target of all the analysts comes to $125. The estimated standard deviation from the target is $14.48.


Johnson & Johnson has lost 0.08% in the last five trading days and dropped 3.73% in the last 4 weeks. Johnson & Johnson is up 6.7% in the last 3-month period. Year-to-Date the stock performance stands at 18.74%. Johnson & Johnson (NYSE:JNJ): stock turned positive on Tuesday. Though the stock opened at $119.67, the bulls momentum made the stock top out at $119.96 level for the day. The stock recorded a low of $119.02 and closed the trading day at $119.44, in the green by 0.26%. The total traded volume for the day was 5,603,177. The stock had closed at $119.13 in the previous days trading.

Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices. The Companys subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.